Abstract:OBJECTIVE To investigate the diagnostic role of Anti-Mullerian Hormone (AMH) in Polycystic ovary syndrome (PCOS) using advanced marginal beta-binomial statistical model and present the optimal cut-off by different age groups, geographical locations, body mass index (BMI) and other relevant factors. DATA SOURCES A comprehensive and systematic literature search was conducted in ISI Web of Science, PubMed/Medline, Scopus, Cochrane Library, Embase and ProQuest until August 2024. STUDY ELIGIBILITY CRITERIA Epidemiological studies whose diagnostic criterion for PCOS was Androgen Excess Society (AES) or National Institute of Health (NIH) or Rotterdam were included in the current meta-analysis. If studies had information about the sensitivity and specificity of AMH or related data thorough which we could calculate these parameters and/or data on odds ratio and mean were eligible to be included. METHODS The diagnostic role of AMH was assessed using the marginal beta-binomial statistical model and summary receiver operating characteristics (SROC) method in terms of pooled sensitivity, specificity, and diagnostic odds ratio (DOR) with 95% confidence interval (CI). Pooled weighted mean difference (WMD) and pooled odds ratios (ORs) with 95% CI were estimated using random effects model. RESULTS A total of 202 observational studies were included in the pooled analysis, of which 106 studies (including 19465 cases and 29318 controls) were used for meta-analysis of sensitivity/specificity and 186 studies (including 30656 cases and 34360 controls) for meta-analysis of mean difference. The pooled sensitivity, specificity, and DOR for AMH were 0.79 (95% CI: 0.52 to 0.97), 0.82 (95% CI: 0.64 to 0.99) and 17.12 (95% CI: 14.37 to 20.32), respectively. The area under curve (AUC) based on the SROC model was 0.90 (95% CI: 0.87 to 0.93). AMH levels were significantly higher in women with PCOS than control women (WMD= 4.91; 95% CI: 4.57–5.27). In addition, individuals with a higher level of AMH were more likely to be affected by PCOS (OR=23.17; 95% CI: 18.74-28.66; I 2 = 94%; P 5.39 ng/mL was associated with PCOS (sensitivity= 88.6%; specificity= 92.75%; likelihood ratio for a positive test result (LR+)= 12.21; and likelihood ratio for a negative test result (LR-)= 0.12). CONCLUSION According to the results of this meta-analysis, serum AMH concentration is a valuable biomarker for the diagnosis of PCOS. The cut-off points suggested by the current meta-analysis need to be evaluated and validated by future studies and before their implementation in clinical practice.

Age‐specific Reference Ranges of Serum Anti‐müllerian Hormone in Healthy Women and Its Application in Diagnosis of Polycystic Ovary Syndrome: a Population Study

SUN-021 Age-Specific Multiples of the Median Level of Serum Anti-Mullerian Hormone is a Potential Marker for Diagnosis of Polycystic Ovary Syndrome

Anti-Müllerian hormone for prediction of ovarian response in Chinese infertile women undergoing IVF/ICSI cycles: a prospective, multi-centre, observational study

Anti-Müllerian Hormone Levels in Women with Polycystic Ovarian Syndrome Compared with Normal Women of Reproductive Age in China

Elevated Serum Anti-Mullerian Hormone in Adolescent and Young Adult Chinese Patients with Polycystic Ovary Syndrome

Age-related curves of AMH using the Gen II, the picoAMH and the Elecsys assays in women with polycystic ovary syndrome

Age-specific Serum Antimüllerian Hormone Levels in Women with and Without Polycystic Ovary Syndrome.

Threshold value of anti-Mullerian hormone for the diagnosis of polycystic ovary syndrome in Chinese women

Role of Anti-Müllerian Hormone and Testosterone in Follicular Growth: a Cross-Sectional Study.

Anti-Müllerian hormone (AMH) in the Diagnosis of Menstrual Disturbance Due to Polycystic Ovarian Syndrome

[A Pilot Study of Serum Anti-Mullerian Hormone in Diagnosis of Polycystic Ovary Syndrome Based on 2012 Chinese Polycystic Ovary Syndrome Diagnosis Criteria].

The Diagnostic Value of Serum Anti-Müllerian Hormone (AMH) Measurement in PCOS

Assessing the clinical diagnostic value of anti-Müllerian hormone in polycystic ovarian syndrome and its correlation with clinical and metabolism indicators

A Model for Predicting Polycystic Ovary Syndrome Using Serum AMH, Menstrual Cycle Length, Body Mass Index and Serum Androstenedione in Chinese Reproductive Aged Population: A Retrospective Cohort Study

Anti-müllerian hormone as a diagnostic biomarker for polycystic ovary syndrome and polycystic ovarian morphology: a systematic review and meta-analysis

New insights into the relationship between Anti-Mullerian Hormone and Polycystic ovary syndrome and its diagnostic accuracy: An updated and extended meta-analysis using marginal beta-binomial model

Utility of Serum Anti-Müllerian Hormone Measurement as Part of Polycystic Ovary Syndrome Diagnosis

Can high serum anti-Müllerian hormone levels predict the phenotypes of polycystic ovary syndrome (PCOS) and metabolic disturbances in PCOS patients?

Analysis of serum anti-Müllerian hormone levels in the main phenotypes of polycystic ovary syndrome

Usage of AMH as a determining test of fertility in women with polycystic ovary 2 syndrome (PCOS)

Age-specific random day serum anti-Mullerian hormone reference values for women of reproductive age in the general population: a large Chinese nationwide population-based survey